Developer docs
API playgroundTry for free, no card

Search company profiles

Cannvalate

Full company profile

uuid0003xdh

Namestring
Cannvalate
Company typeenum
Private
Founded yearint
2018
Descriptiontext

Cannvalate is an Australian medical cannabis company founded in 2018 and headquartered in Melbourne. Per the firm's own positioning, it operates across two stated pillars: nutraceuticals and drug discovery within the medical cannabis sector, with a headcount band of 11–50 employees.

The company's public digital footprint is unusually thin for a firm of its stated scale. Its corporate website at cannvalate.com.au currently displays only a placeholder page indicating the site is under redevelopment, and the listed business-enquiry email is routed to contact@blackboxmedia.au, a third-party media address rather than a direct corporate channel. The firmographic, product, technology, customer, pricing, partnership, awards, and operating-geographies records in the available data are empty or unpopulated, and no products, services, certifications, or distribution channels are publicly disclosed. The website footer itself describes cannvalate.com.au as a domain-registrant service providing advertising links, suggesting the corporate web presence is in a parked or transitional state.

Leadership is the most concrete element of the public record: CEO Sud Agarwal leads the company alongside co-founders Asaf Katz (Chief Commercial Officer) and Darryl Davies (Chief Operating Officer). The only documented capital event is a $4,000,000 funding round (labeled Round 2) closed on 2018-11-07, with investors and lead investor unspecified. No subsequent capital raises, product launches, partnerships, regulatory milestones, or operational metrics have been disclosed, which materially limits independent verification of the company's current commercial activity.

Short descriptiontext

Cannvalate is a private Australian medical cannabis company founded in 2018 and headquartered in Melbourne, operating in nutraceuticals and drug discovery. Led by CEO Sud Agarwal and co-founders Asaf Katz and Darryl Davies, it employs 11–50 staff.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Keyword5 values
medical cannabis, nutraceutical products, drug discovery, cannabis therapeutics, pharmaceutical research
Industry2 codes
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Medical Cannabis Pharmaceuticals
No data
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Cannvalate is a medical cannabis firm that develops and provides nutraceuticals and drug discovery services. Founded in 2018 and headquartered in Melbourne, Australia, the company operates in the medical cannabis industry with a small team of 11-50 employees focused on cannabis-based nutraceutical products and pharmaceutical research.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Nutraceuticals
Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Australian licensed medicinal cannabis cultivator and manufacturer that supplies extracted and formulated cannabinoid products to patients and partners — directly comparable geography, regulatory regime, and clinical-product focus to Cannvalate.

TypeDirect peer
Description

Australian-listed medicinal cannabis producer and distributor of formulated cannabis oils and flower products — similar Australian footprint and clinical-product mix to Cannvalate.

TypeDirect peer
Description

Australian-listed company selling hemp-derived nutraceutical and cannabinoid wellness products globally — directly overlaps with Cannvalate's nutraceutical activity in the cannabis-adjacent consumer health category.

TypeDirect peer
Description

Clinical-stage cannabinoid therapeutics company running drug-discovery and formulation programs targeting specific indications — directly comparable to Cannvalate's drug-discovery and nutraceutical positioning.

TypeDirect peer
Description

Australia-based medical cannabis company selling formulated cannabinoid products through a pharmacy and prescriber network — closely mirrors Cannvalate's clinical-cannabis + patient-services model.

TypeDirect peer
Description

Australian medical cannabis company developing and supplying cannabinoid-based pharmaceutical products to prescribers — comparable in clinical/pharmaceutical positioning and Australian regulatory environment to Cannvalate.

7Medlab Clinical
TypeDirect peer
Description

Australian pharmaceutical company developing cannabis-based and other prescription therapeutics for specific indications — comparable drug-discovery and clinical-pharma focus in the same regulatory environment.

TypeBroad incumbent
Description

Australian hemp and cannabis company with nutraceutical (Ananda Health) and medicinal cannabis divisions — comparable breadth across nutraceuticals and cannabis therapeutics.

9MGC Pharmaceuticals
TypeDirect peer
Description

Australia/UK-based cannabis pharmaceutical company developing phytocannabinoid-derived prescription medicines and nutraceuticals — comparable clinical/pharmaceutical and nutraceutical dual model.

TypeBroad incumbent
Description

Australia-based investment company with exposure across medicinal cannabis cultivation, products, and pharma R&D — a broader portfolio player in the same clinical-cannabis space Cannvalate operates in.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cannvalate

Medical Cannabis Pharmaceuticalscannvalate.com.au

Cannvalate is a private Australian medical cannabis company founded in 2018 and headquartered in Melbourne, operating in nutraceuticals and drug discovery. Led by CEO Sud Agarwal and co-founders Asaf Katz and Darryl Davies, it employs 11–50 staff.

What Cannvalate does

Cannvalate is an Australian medical cannabis company founded in 2018 and headquartered in Melbourne. Per the firm's own positioning, it operates across two stated pillars: nutraceuticals and drug discovery within the medical cannabis sector, with a headcount band of 11–50 employees.

The company's public digital footprint is unusually thin for a firm of its stated scale. Its corporate website at cannvalate.com.au currently displays only a placeholder page indicating the site is under redevelopment, and the listed business-enquiry email is routed to contact@blackboxmedia.au, a third-party media address rather than a direct corporate channel. The firmographic, product, technology, customer, pricing, partnership, awards, and operating-geographies records in the available data are empty or unpopulated, and no products, services, certifications, or distribution channels are publicly disclosed. The website footer itself describes cannvalate.com.au as a domain-registrant service providing advertising links, suggesting the corporate web presence is in a parked or transitional state.

Leadership is the most concrete element of the public record: CEO Sud Agarwal leads the company alongside co-founders Asaf Katz (Chief Commercial Officer) and Darryl Davies (Chief Operating Officer). The only documented capital event is a $4,000,000 funding round (labeled Round 2) closed on 2018-11-07, with investors and lead investor unspecified. No subsequent capital raises, product launches, partnerships, regulatory milestones, or operational metrics have been disclosed, which materially limits independent verification of the company's current commercial activity.

Cannvalate firmographics

Firmographics
Name
Cannvalate
Website
https://cannvalate.com.au
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
Cannvalate is a private Australian medical cannabis company founded in 2018 and headquartered in Melbourne, operating in nutraceuticals and drug discovery. Led by CEO Sud Agarwal and co-founders Asaf Katz and Darryl Davies, it employs 11–50 staff.
Ownership category
akta.pro rank

Cannvalate industry classification

Industry
Product category
Medical Cannabis Pharmaceuticals
NAICS
Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYCRANAFAI
Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Medical cannabis
  • Nutraceutical products
  • Drug discovery
  • Cannabis therapeutics
  • Pharmaceutical research

Where Cannvalate is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Markets served

Cannvalate business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations

Cannvalate product offering

Product offering

Core offering

Cannvalate is a medical cannabis firm that develops and provides nutraceuticals and drug discovery services. Founded in 2018 and headquartered in Melbourne, Australia, the company operates in the medical cannabis industry with a small team of 11-50 employees focused on cannabis-based nutraceutical products and pharmaceutical research.

Differentiator

Problem solved

Functional benefit

Products and services

  • Nutraceuticals

Companies that use Cannvalate

Customer profile

Ideal customer profiles1 record

Cannvalate technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Cannvalate partnerships and signals

Strategic signal

Recent moves3 records

Expansion highlights1 record

Cannvalate competitors and assessment

Company assessment

Direct peers

  • Cann Group Limited: Australian licensed medicinal cannabis cultivator and manufacturer that supplies extracted and formulated cannabinoid products to patients and partners — directly comparable geography, regulatory regime, and clinical-product focus to Cannvalate.
  • Little Green Pharma: Australian-listed medicinal cannabis producer and distributor of formulated cannabis oils and flower products — similar Australian footprint and clinical-product mix to Cannvalate.
  • Elixinol Wellness: Australian-listed company selling hemp-derived nutraceutical and cannabinoid wellness products globally — directly overlaps with Cannvalate's nutraceutical activity in the cannabis-adjacent consumer health category.
  • Zelira Therapeutics: Clinical-stage cannabinoid therapeutics company running drug-discovery and formulation programs targeting specific indications — directly comparable to Cannvalate's drug-discovery and nutraceutical positioning.
  • Althea Group Holdings: Australia-based medical cannabis company selling formulated cannabinoid products through a pharmacy and prescriber network — closely mirrors Cannvalate's clinical-cannabis + patient-services model.
  • AusCann Group Holdings: Australian medical cannabis company developing and supplying cannabinoid-based pharmaceutical products to prescribers — comparable in clinical/pharmaceutical positioning and Australian regulatory environment to Cannvalate.
  • Medlab Clinical: Australian pharmaceutical company developing cannabis-based and other prescription therapeutics for specific indications — comparable drug-discovery and clinical-pharma focus in the same regulatory environment.
  • MGC Pharmaceuticals: Australia/UK-based cannabis pharmaceutical company developing phytocannabinoid-derived prescription medicines and nutraceuticals — comparable clinical/pharmaceutical and nutraceutical dual model.

Broad incumbents

  • Ecofibre: Australian hemp and cannabis company with nutraceutical (Ananda Health) and medicinal cannabis divisions — comparable breadth across nutraceuticals and cannabis therapeutics.
  • MMJ Group Holdings: Australia-based investment company with exposure across medicinal cannabis cultivation, products, and pharma R&D — a broader portfolio player in the same clinical-cannabis space Cannvalate operates in.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Cannvalate financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cannvalate leadership team

Management profile

Number of profiles

Profiles3 records

Cannvalate funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cannvalate M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cannvalate

What does Cannvalate do?

Cannvalate is a medical cannabis firm that develops and provides nutraceuticals and drug discovery services. Founded in 2018 and headquartered in Melbourne, Australia, the company operates in the medical cannabis industry with a small team of 11-50 employees focused on cannabis-based nutraceutical products and pharmaceutical research.

When was Cannvalate founded?

Cannvalate was founded in 2018. It employs 11 to 50 people.

Where is Cannvalate based?

Cannvalate is headquartered in Melbourne, Australia, in the Oceania region.

Who are Cannvalate's main competitors?

Direct peers on record are Cann Group Limited, Little Green Pharma, Elixinol Wellness, Zelira Therapeutics, Althea Group Holdings, AusCann Group Holdings, Medlab Clinical and MGC Pharmaceuticals. Broad incumbents are Ecofibre and MMJ Group Holdings.

Does Cannvalate have an API?

No public API is recorded for Cannvalate.

What industry is Cannvalate in?

Cannvalate's product category is Medical Cannabis Pharmaceuticals. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services), with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 325411 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals